Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) 20.1% HIGHER; announced that R788 produced significant clinical improvement in rheumatoid arthritis patients in the recently completed TASKi2 Phase 2b clinical trial of 457 patients treated for up to 6 months. The groups treated with 100 mg of R788 bid and 150 mg qd (once a day) reported higher ACR 20, ACR 50, ACR 70 and DAS28 response rates than the placebo group. Click here for the full report.
PURE Bioscience (Nasdaq: PURE) 17.8% HIGHER; could be surging on reports that the Obama administration, as well as other worldwide oficials, could be preparing for another wave of the A/H1N1 flu virus.
Novagen (Nasdaq: NVGN) 16.2% LOWER; shares seem to be correcting this morning after 2 straight days of upside on the back of news that Marshall Edwards reported its phenoxodiol kills rapidly proliferating T-cells. The stock surged about 80% over the last 2 ...
Hansen Medical, Inc. (NASDAQ: HNSN) 32.8% LOWER; Hansen shipped six Sensei Robotic Catheter Systems and expects to recognize revenue in Q2 on the sale of three of these systems. Sees Q2 sales of $3.1-$3.3 million, versus the consensus of $8.77 million. In addition to the three Sensei systems, revenues for the quarter are expected to include the shipment of approximately 626 Artisan catheters, approximately 100 of which were sold to a single international medical center. Click here for the full report.
GenCorp Inc. (NYSE: GY) 19.5% HIGHER; reports Q2 EPS of $0.18, compared to $0.12 in the same quarter last year ...
